APR 07, 2015 10:15 PM PDT

Cancer Drug Shows Promise for Treating Stroke

WRITTEN BY: Ilene Schneider
A University of Victoria neuroscientist has discovered that a cancer drug may improve recovery rates for diabetic patients who have suffered a stroke.
The reasons behind the poorer prognosis for stroke recovery are unknown.
"A big challenge in treating stroke is understanding how other health conditions affect recovery," said Craig Brown, a neuroscientist in UVic's Division of Medical Sciences "Many diseases increase the chances of having a stroke, and they also limit recovery. Diabetes is one of these diseases, affecting millions in Canada. Much like a poker hand, the unique collection of health concerns a patient holds in their hand likely dictates how they should be treated."

The reasons behind the poorer prognosis for stroke recovery are unknown. However Brown's neurobiology lab is providing new clues.

"What we've found is that diabetic mice have leakier blood vessels in the brain after stroke than mice without diabetes. These leakier vessels lead to greater movement of proteins and other damaging elements of blood plasma into the brain, a process that is normally regulated in a strict manner to protect brain health," he explains.

The study traces the cause of leaky vessels to excessive vascular endothelial growth factor (VEGF) signaling, which regulates the growth and permeability of blood vessels. Fortunately, several drugs, known as VEGF inhibitors, have been developed over the last few decades to block cancerous tumours from growing new blood vessels and spreading.

Brown's lab used one of these cancer drugs in mouse models to see if they could reduce blood vessel leakage and the damaging effects of stroke.

The treatment not only helped reduce the leakiness of blood vessels, but it also prevented the loss of neural connections and improved the recovery of sensory-motor function-a discovery that could lead to better recovery rates for diabetic patients.

Quite surprisingly, however, the same treatment had no benefits in non-diabetic mice, suggesting that when it comes to betting on a stroke treatment, you really have to know what cards you're holding.

Source: University of Victoria
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 04, 2019
Technology
NOV 04, 2019
Can Screen-Time Structurally Affect a Child's Brain?
A study published in JAMA Pediatrics concludes that preschool-age children who have more screen time negatively impact regions of the brain involved with s...
NOV 10, 2019
Neuroscience
NOV 10, 2019
Gene Mutation Identified that Protects Agaist Dementia
For over two decades, researchers have been studying an extended family of over 1,200 people from Columbia known for having a rare genetic mutation that le...
DEC 13, 2019
Genetics & Genomics
DEC 13, 2019
Top Autism Gene Linked to Being Taller and Having a Big Head
People who carry certain mutations in gene CHD8, a gene strongly linked to autism, tend to be taller and have larger heads than the average person. They al...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
JAN 13, 2020
Neuroscience
JAN 13, 2020
A Quarter of Children with Autism are Left Undiagnosed
Researchers from Rutgers University have found that 25% of children under the age of 8 with autism in the US are left undiagnosed, something that may be a ...
FEB 06, 2020
Clinical & Molecular DX
FEB 06, 2020
Concussion detector could pick up concussions in athletes, right from the sidelines
Concussions are brain traumas caused by a blow to the head or a whiplash injury. The risk of concussions are greatly heightened in athletes playing high co...
Loading Comments...